Last 12 months
Inside the activity.
0 purchase rows · 39 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 2 |
| Dec 2025 | 0 | 6 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 21 |
| Apr 2026 | 0 | 7 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 04, 2026 Filed Aug 6, 2026 20:13 UTC |
Gheuens SarahChief Medical Officer
|
SaleCommon stock | 30,000 | $30.48 | $914,400.00 |
DisclosureSEC source: 0001439222-26-000120 · wk-form4_1786047196.xml · nonDerivative · entry 1 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,645 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $30.25 to $30.88. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 08, 2026 Filed Jul 10, 2026 16:18 UTC |
Backstrom Jay T.Director
|
Exercise / conversionRestricted stock units · Derivative | 1,447 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000112 · wk-form4_1783714678.xml · derivative · entry 2 Backstrom Jay T. · CIK 0001796398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,894 Underlying: Common stock · 1,447 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on July 8, 2025. Beginning on July 8, 2026, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on July 8, 2025. Beginning on July 8, 2026, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| July 08, 2026 Filed Jul 10, 2026 16:18 UTC |
Backstrom Jay T.Director
|
GrantCommon stock | 1,447 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000112 · wk-form4_1783714678.xml · nonDerivative · entry 1 Backstrom Jay T. · CIK 0001796398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,447 Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 20:03 UTC |
Gheuens SarahChief Medical Officer
|
Exercise / conversionRestricted stock units · Derivative | 8,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000110 · wk-form4_1783022592.xml · derivative · entry 3 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 8,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on July 1, 2023. Beginning on July 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. F3 · derivative.expiration_date: The restricted stock units were granted on July 1, 2023. Beginning on July 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 20:03 UTC |
Gheuens SarahChief Medical Officer
|
SaleCommon stock | 4,007 | $37.56 | $150,502.92 |
DisclosureSEC source: 0001439222-26-000110 · wk-form4_1783022592.xml · nonDerivative · entry 2 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,645 F1 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated July 1, 2023. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 20:03 UTC |
Gheuens SarahChief Medical Officer
|
Exercise / conversionCommon stock | 8,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000110 · wk-form4_1783022592.xml · nonDerivative · entry 1 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,652 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:13 UTC |
Milanova TsvetaChief Commercial Officer
|
GrantRestricted stock units · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000081 · wk-form4_1782249197.xml · derivative · entry 2 Milanova Tsveta · CIK 0001957180 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common stock · 3,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service. F2 · derivative.expiration_date: Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:13 UTC |
Milanova TsvetaChief Commercial Officer
|
Exercise / conversionPerformance share units · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000081 · wk-form4_1782249197.xml · derivative · entry 1 Milanova Tsveta · CIK 0001957180 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common stock · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service. F2 · derivative.expiration_date: Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:15 UTC |
Gheuens SarahChief Medical Officer
|
GrantRestricted stock units · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000085 · wk-form4_1782249348.xml · derivative · entry 2 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common stock · 3,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service. F2 · derivative.expiration_date: Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:15 UTC |
Gheuens SarahChief Medical Officer
|
Exercise / conversionPerformance share units · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000085 · wk-form4_1782249348.xml · derivative · entry 1 Gheuens Sarah · CIK 0001881190 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common stock · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service. F2 · derivative.expiration_date: Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:21 UTC |
Owen Adams CatherineDirector
|
GrantStock options (right to buy) · Derivative | 14,950 | $0.00 Strike: $34.16 | $0.00 |
DisclosureSEC source: 0001439222-26-000097 · wk-form4_1782249676.xml · derivative · entry 4 Owen Adams Catherine · CIK 0001816838 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,950 Underlying: Common stock · 14,950 shares Expires 2036-06-18 F4 · derivative.exercise_date: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:21 UTC |
Owen Adams CatherineDirector
|
GrantRestricted stock units · Derivative | 2,927 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000097 · wk-form4_1782249676.xml · derivative · entry 3 Owen Adams Catherine · CIK 0001816838 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,927 Underlying: Common stock · 2,927 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:21 UTC |
Owen Adams CatherineDirector
|
Exercise / conversionRestricted stock units · Derivative | 2,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000097 · wk-form4_1782249676.xml · derivative · entry 2 Owen Adams Catherine · CIK 0001816838 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 2,816 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:21 UTC |
Owen Adams CatherineDirector
|
Exercise / conversionCommon stock | 2,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000097 · wk-form4_1782249676.xml · nonDerivative · entry 1 Owen Adams Catherine · CIK 0001816838 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,865 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:25 UTC |
Ballal Rahul D.Director
|
GrantStock options (right to buy) · Derivative | 14,950 | $0.00 Strike: $34.16 | $0.00 |
DisclosureSEC source: 0001439222-26-000107 · wk-form4_1782249916.xml · derivative · entry 4 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,950 Underlying: Common stock · 14,950 shares Expires 2036-06-18 F4 · derivative.exercise_date: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:25 UTC |
Ballal Rahul D.Director
|
GrantRestricted stock units · Derivative | 2,927 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000107 · wk-form4_1782249916.xml · derivative · entry 3 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,927 Underlying: Common stock · 2,927 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:25 UTC |
Ballal Rahul D.Director
|
Exercise / conversionRestricted stock units · Derivative | 2,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000107 · wk-form4_1782249916.xml · derivative · entry 2 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 2,816 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:25 UTC |
Ballal Rahul D.Director
|
Exercise / conversionCommon stock | 2,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000107 · wk-form4_1782249916.xml · nonDerivative · entry 1 Ballal Rahul D. · CIK 0001805097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,230 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:12 UTC |
Backstrom Jay T.Director
|
GrantStock options (right to buy) · Derivative | 14,950 | $0.00 Strike: $34.16 | $0.00 |
DisclosureSEC source: 0001439222-26-000079 · wk-form4_1782249139.xml · derivative · entry 2 Backstrom Jay T. · CIK 0001796398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,950 Underlying: Common stock · 14,950 shares Expires 2036-06-18 F3 · derivative.exercise_date: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:12 UTC |
Backstrom Jay T.Director
|
GrantRestricted stock units · Derivative | 2,927 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000079 · wk-form4_1782249139.xml · derivative · entry 1 Backstrom Jay T. · CIK 0001796398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,927 Underlying: Common stock · 2,927 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:24 UTC |
CAPELLO JEFFREY DDirector
|
GrantStock options (right to buy) · Derivative | 14,950 | $0.00 Strike: $34.16 | $0.00 |
DisclosureSEC source: 0001439222-26-000105 · wk-form4_1782249875.xml · derivative · entry 4 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,950 Underlying: Common stock · 14,950 shares Expires 2036-06-18 F4 · derivative.exercise_date: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:24 UTC |
CAPELLO JEFFREY DDirector
|
GrantRestricted stock units · Derivative | 2,927 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000105 · wk-form4_1782249875.xml · derivative · entry 3 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,927 Underlying: Common stock · 2,927 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:24 UTC |
CAPELLO JEFFREY DDirector
|
Exercise / conversionRestricted stock units · Derivative | 2,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000105 · wk-form4_1782249875.xml · derivative · entry 2 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 2,816 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:24 UTC |
CAPELLO JEFFREY DDirector
|
Exercise / conversionCommon stock | 2,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000105 · wk-form4_1782249875.xml · nonDerivative · entry 1 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,865 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:23 UTC |
Foster-Cheek Kaye IDirector
|
GrantStock options (right to buy) · Derivative | 14,950 | $0.00 Strike: $34.16 | $0.00 |
DisclosureSEC source: 0001439222-26-000103 · wk-form4_1782249832.xml · derivative · entry 5 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,950 Underlying: Common stock · 14,950 shares Expires 2036-06-18 F4 · derivative.exercise_date: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:23 UTC |
Foster-Cheek Kaye IDirector
|
GrantRestricted stock units · Derivative | 2,927 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000103 · wk-form4_1782249832.xml · derivative · entry 4 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,927 Underlying: Common stock · 2,927 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:23 UTC |
Foster-Cheek Kaye IDirector
|
Exercise / conversionRestricted stock units · Derivative | 2,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000103 · wk-form4_1782249832.xml · derivative · entry 3 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 2,816 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:23 UTC |
Foster-Cheek Kaye IDirector
|
Exercise / conversionCommon stock | 2,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000103 · wk-form4_1782249832.xml · nonDerivative · entry 1 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,284 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:21 UTC |
Ho MaykinDirector
|
GrantStock options (right to buy) · Derivative | 14,950 | $0.00 Strike: $34.16 | $0.00 |
DisclosureSEC source: 0001439222-26-000099 · wk-form4_1782249717.xml · derivative · entry 4 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,950 Underlying: Common stock · 14,950 shares Expires 2036-06-18 F4 · derivative.exercise_date: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:21 UTC |
Ho MaykinDirector
|
GrantRestricted stock units · Derivative | 2,927 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000099 · wk-form4_1782249717.xml · derivative · entry 3 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,927 Underlying: Common stock · 2,927 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:21 UTC |
Ho MaykinDirector
|
Exercise / conversionRestricted stock units · Derivative | 2,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000099 · wk-form4_1782249717.xml · derivative · entry 2 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 2,816 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:21 UTC |
Ho MaykinDirector
|
Exercise / conversionCommon stock | 2,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000099 · wk-form4_1782249717.xml · nonDerivative · entry 1 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,848 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:22 UTC |
FOUSE JACQUALYN ADirector
|
GrantStock options (right to buy) · Derivative | 14,950 | $0.00 Strike: $34.16 | $0.00 |
DisclosureSEC source: 0001439222-26-000101 · wk-form4_1782249776.xml · derivative · entry 4 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,950 Underlying: Common stock · 14,950 shares Expires 2036-06-18 F4 · derivative.exercise_date: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:22 UTC |
FOUSE JACQUALYN ADirector
|
GrantRestricted stock units · Derivative | 2,927 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000101 · wk-form4_1782249776.xml · derivative · entry 3 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,927 Underlying: Common stock · 2,927 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:22 UTC |
FOUSE JACQUALYN ADirector
|
Exercise / conversionRestricted stock units · Derivative | 2,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000101 · wk-form4_1782249776.xml · derivative · entry 2 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 2,816 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:22 UTC |
FOUSE JACQUALYN ADirector
|
Exercise / conversionCommon stock | 2,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000101 · wk-form4_1782249776.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:20 UTC |
Scadden DavidDirector
|
GrantStock options (right to buy) · Derivative | 14,950 | $0.00 Strike: $34.16 | $0.00 |
DisclosureSEC source: 0001439222-26-000095 · wk-form4_1782249639.xml · derivative · entry 4 Scadden David · CIK 0001707715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,950 Underlying: Common stock · 14,950 shares Expires 2036-06-18 F4 · derivative.exercise_date: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:20 UTC |
Scadden DavidDirector
|
GrantRestricted stock units · Derivative | 2,927 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000095 · wk-form4_1782249639.xml · derivative · entry 3 Scadden David · CIK 0001707715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,927 Underlying: Common stock · 2,927 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:20 UTC |
Scadden DavidDirector
|
Exercise / conversionRestricted stock units · Derivative | 2,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000095 · wk-form4_1782249639.xml · derivative · entry 2 Scadden David · CIK 0001707715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 2,816 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:20 UTC |
Scadden DavidDirector
|
Exercise / conversionCommon stock | 2,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000095 · wk-form4_1782249639.xml · nonDerivative · entry 1 Scadden David · CIK 0001707715 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:19 UTC |
Smith CynthiaDirector
|
GrantStock options (right to buy) · Derivative | 14,950 | $0.00 Strike: $34.16 | $0.00 |
DisclosureSEC source: 0001439222-26-000093 · wk-form4_1782249570.xml · derivative · entry 4 Smith Cynthia · CIK 0001609480 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,950 Underlying: Common stock · 14,950 shares Expires 2036-06-18 F4 · derivative.exercise_date: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:19 UTC |
Smith CynthiaDirector
|
GrantRestricted stock units · Derivative | 2,927 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000093 · wk-form4_1782249570.xml · derivative · entry 3 Smith Cynthia · CIK 0001609480 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,927 Underlying: Common stock · 2,927 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:19 UTC |
Smith CynthiaDirector
|
Exercise / conversionRestricted stock units · Derivative | 2,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000093 · wk-form4_1782249570.xml · derivative · entry 2 Smith Cynthia · CIK 0001609480 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 2,816 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:19 UTC |
Smith CynthiaDirector
|
Exercise / conversionCommon stock | 2,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000093 · wk-form4_1782249570.xml · nonDerivative · entry 1 Smith Cynthia · CIK 0001609480 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,230 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:17 UTC |
Goff BrianDirector · Chief Executive Officer
|
GrantRestricted stock units · Derivative | 39,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000089 · wk-form4_1782249456.xml · derivative · entry 2 Goff Brian · CIK 0001546216 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,000 Underlying: Common stock · 39,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service. F2 · derivative.expiration_date: Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:17 UTC |
Goff BrianDirector · Chief Executive Officer
|
Exercise / conversionPerformance share units · Derivative | 39,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000089 · wk-form4_1782249456.xml · derivative · entry 1 Goff Brian · CIK 0001546216 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,000 Underlying: Common stock · 39,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service. F2 · derivative.expiration_date: Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:18 UTC |
Viswanadhan KrishnanChief Strategy and Operations
|
GrantRestricted stock units · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000091 · wk-form4_1782249510.xml · derivative · entry 2 Viswanadhan Krishnan · CIK 0001999913 · Chief Strategy and Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common stock · 3,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: Performance stock units were granted on March 5, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service. F2 · derivative.expiration_date: Performance stock units were granted on March 5, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:18 UTC |
Viswanadhan KrishnanChief Strategy and Operations
|
Exercise / conversionPerformance share units · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000091 · wk-form4_1782249510.xml · derivative · entry 1 Viswanadhan Krishnan · CIK 0001999913 · Chief Strategy and Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common stock · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: Performance stock units were granted on March 5, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service. F2 · derivative.expiration_date: Performance stock units were granted on March 5, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:16 UTC |
Burns James WilliamChief Legal Officer
|
GrantRestricted stock units · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000087 · wk-form4_1782249398.xml · derivative · entry 2 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common stock · 3,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service. F2 · derivative.expiration_date: Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:16 UTC |
Burns James WilliamChief Legal Officer
|
Exercise / conversionPerformance share units · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000087 · wk-form4_1782249398.xml · derivative · entry 1 Burns James William · CIK 0001900772 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common stock · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service. F2 · derivative.expiration_date: Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.